NEW YORK (GenomeWeb News) - DNA Direct and Iverson Genetic Diagnostics said today that they are collaborating to provide personalized reports for customers of Iverson's warfarin-sensitivity assay.
Under the terms of the agreement, DNA Direct will provide a customized, web-based report for Iverson customers that will explain their test results in a “patient-friendly, interactive format,” the companies said.
The reports will be “personalized to the patient's test results,” the companies said, and will explain the implications for both general drug response and warfarin dosing, as well as how genes affect drug response, what factors impact dosing of the blood thinner, and what next steps may be most appropriate.
Patients will be able to download a copy of their lab report, as well as a clinical summary letter that they can share with their physicians.
Iverson’s Warfarin Dosing Panel XP identifies seven different variations of the CYP2C9 gene and nine different variations of the VKORC1 gene that play a role in determining response to warfarin.